Prevalence of @entity29 related @entity1141 and XXXX in 1500 colonoscopies from a referral center in northwestern Greece.

@entity1 @entity1944 @entity5 @entity4272 @entity1050 @entity29 @entity1960 @entity13570 @entity30 @entity2983 @entity1141
BACKGROUND AND AIM: To report on the prevalence of @entity29 ( @entity29 ) related @entity1944 and @entity5 in northwestern Greece. @entity1 AND METHODS: Single referral center retrospective study. The policy among all gastroenterologists of the area regarding medical treatment, @entity1 follow up and bowel surveillance strategies including risk factors is the same. RESULTS: We analyzed 1494 colonoscopies from 696 consecutive @entity29 @entity1 (494 UC). The follow up time [median, IQR] was 16 [8-23] years and the age at diagnosis was 28 [21-49] years. The number of @entity1 years at risk was 16.219. Disease location for UC was: pancolitis 761 (59%), @entity1960 455 (35%), and @entity4272 69 (6%). Disease location for @entity1050 was: colitis 142 (66%), @entity13570 45 (22%) and @entity30 21 (10%). Disease activity was in remission in 1240 (83%) of them. In total, 498 (72%) @entity1 were on @entity2983 , 169(24%) on immunosuppression and 29 (4%) on biologicals. Biopsies were taken randomly in 1429 (96%) endoscopies and were targeted in 65 (4%) of them. We recorded 69 (9.4%) cases with @entity1141 and 10 (1.4%) cases with @entity5 (9 in UC). No difference was found for @entity1141 and @entity5 in @entity1 who followed up for 10-20 years or for more than 20 years. CONCLUSIONS: The prevalence of @entity1141 and @entity5 is increased in UC compared to @entity1050 but the prevalence of high-grade @entity1141 is comparatively low. @entity5 prevalence is increasing after the first decade and then practically remains stable.
